Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cellectis Inc.
< Previous
1
2
Next >
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
September 27, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
August 07, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
August 03, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
July 27, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
July 12, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
June 28, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
June 09, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
June 05, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
May 31, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
May 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
May 12, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
May 11, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
May 04, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 02, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
April 27, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
April 24, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
April 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
April 11, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
April 04, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
March 14, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 08, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
March 06, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
CLXT
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
March 01, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
February 07, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
February 03, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces Pricing of Follow-On Offering
February 03, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces Launch of Follow-On Offering
February 02, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
January 20, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
January 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
CLXT
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
December 29, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright